Pro-inflammatory eicosanoid biosynthesis enzyme

Pro-inflammatory eicosanoid biosynthesis enzymes are a group of enzymes responsible for the production of pro-inflammatory lipid mediators known as eicosanoids. The main classes include cyclooxygenases (COX‑1 and COX‑2), which generate prostaglandins and thromboxanes; lipoxygenases, which produce leukotrienes and lipoxins; and cytochrome P450 epoxygenases, which form other oxidized derivatives. These enzymes act on polyunsaturated fatty acids such as arachidonic acid released from membrane phospholipids by phospholipase A2. Their products play central roles in mediating inflammation, pain, fever, immune cell recruitment, vascular changes, and are implicated in diseases like arthritis, cancer, asthma, and cardiovascular disorders. Drugs targeting these enzymes—such as NSAIDs or specific leukotriene pathway inhibitors—are widely used to treat inflammatory conditions but can have notable side effects including gastrointestinal injury or increased cardiovascular risk[1][3][4]. Note: "Pro-inflammatory eicosanoid biosynthesis enzymes" is not a single molecular target but rather refers collectively to several distinct enzyme families involved in the generation of pro-inflammatory lipid mediators. For structured data purposes or drug discovery efforts it is preferable to specify individual targets such as "Cyclooxygenase 1", "Cyclooxygenase 2", "5-Lipoxygenase", etc.[1][3]

Other names

Cyclooxygenase (COX)Lipoxygenase (LOX)Cytochrome P450 epoxygenase (CYP)Phospholipase A2 (PLA2)

Inhibition of cyclooxygenase to reduce prostaglandin synthesis and inflammation Inhibition of lipoxygenase to reduce leukotriene production